The increasing incidence of uterine cancers in younger women

Objectives: To evaluate the incidence and genetic profiling trends in uterine cancer for women younger than 50 years of age in the United States. Methods: Incidence rates were estimated from the United States Cancer Statistics (USCS) program for uterine cancers diagnosed at < 50 years old between 2001 and 2016 after correcting for hysterectomy and pregnancy prevalence from the Behavioral Risk Factor Surveillance System. SEER*Stat and Joinpoint regression were used to calculate the incidence rate (per 100,000) and average annual percent change (AAPC). Data from National Cancer Institute Genomic Data Commons Data Portal including The Cancer Genome Atlas Program (TCGA) were obtained to compare genomic profiles by age. Results: There were 93,693 eligible women diagnosed <50 years old with uterine cancer between 2001 to 2016. The highest incidence was reported for women between the ages of 45 and 49 years old (33.84/100,000) compared with the younger cohorts (<45 years old). In addition, uterine cancer incidence per 100,000 increased between 2001 and 2016 for each age group<45 years of age including those 30-34 years old (3.8 to 5.8), 35-39 years old (7.7 to 11.4) and 40-44 years old (15.8 to 19.9, all p<0.001). The highest annual increase in uterine cancer diagnosed in the 30-34 year old age group was 4.4% for Hispanic women compared with 3.5% for Black women and 1.5% for White women. We then evaluated a panel of targetable molecular markers in young women diagnosed with uterine cancer at <50 years old (n=96) relative to older women diagnosed ≥50 years old (n=1,005). Tumors from younger women were more likely to express BRCA1 (11% vs. 4%; P=0.004), BRCA2 (14% vs. 8%; P=0.06), CDK12 (9% vs 4%; P=0.02), POLE (15% vs 8%; P=0.02), and less likely to express TP53 (14% vs 27%; P=0.005). Conclusions: The incidence of uterine cancer in young women is increasing in the United States, especially for Black and Hispanic women. Tumors from younger patients may have molecular markers associated with targetable agents and may portend better prognosis. To evaluate the incidence and genetic profiling trends in uterine cancer for women younger than 50 years of age in the United States. Incidence rates were estimated from the United States Cancer Statistics (USCS) program for uterine cancers diagnosed at < 50 years old between 2001 and 2016 after correcting for hysterectomy and pregnancy prevalence from the Behavioral Risk Factor Surveillance System. SEER*Stat and Joinpoint regression were used to calculate the incidence rate (per 100,000) and average annual percent change (AAPC). Data from National Cancer Institute Genomic Data Commons Data Portal including The Cancer Genome Atlas Program (TCGA) were obtained to compare genomic profiles by age. There were 93,693 eligible women diagnosed <50 years old with uterine cancer between 2001 to 2016. The highest incidence was reported for women between the ages of 45 and 49 years old (33.84/100,000) compared with the younger cohorts (<45 years old). In addition, uterine cancer incidence per 100,000 increased between 2001 and 2016 for each age group<45 years of age including those 30-34 years old (3.8 to 5.8), 35-39 years old (7.7 to 11.4) and 40-44 years old (15.8 to 19.9, all p<0.001). The highest annual increase in uterine cancer diagnosed in the 30-34 year old age group was 4.4% for Hispanic women compared with 3.5% for Black women and 1.5% for White women. We then evaluated a panel of targetable molecular markers in young women diagnosed with uterine cancer at <50 years old (n=96) relative to older women diagnosed ≥50 years old (n=1,005). Tumors from younger women were more likely to express BRCA1 (11% vs. 4%; P=0.004), BRCA2 (14% vs. 8%; P=0.06), CDK12 (9% vs 4%; P=0.02), POLE (15% vs 8%; P=0.02), and less likely to express TP53 (14% vs 27%; P=0.005). The incidence of uterine cancer in young women is increasing in the United States, especially for Black and Hispanic women. Tumors from younger patients may have molecular markers associated with targetable agents and may portend better prognosis.